Fewer patients will be receiving the erythropoiesis-stimulating agents Eprex (epoetin) and Aranesp (darbepoetin)

Fewer patients will be receiving the erythropoiesis-stimulating agents Eprex (epoetin) and Aranesp (darbepoetin).

Chronic kidney disease. Erythropoiesis-stimulating agents (ESAs) are associated with an increase in death and cardiovascular events when used to boost hemoglobin above 120 g/L.

These drugs can increase thrombosis risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote